Silence Therapeutics - Mallinckrodt Exercise of Options
Silence Announces Mallinckrodt Exercise of Options for Two Additional Complement Targets
Silence eligible to receive up to
Double-digit royalties on net sales
The collaboration between Silence and Mallinckrodt is aimed at the development and commercialisation of RNA therapeutics designed to inhibit or 'silence' the complement cascade, a group of proteins that are involved in the immune system and that play a role in the development of inflammation. These proteins are known to contribute to the pathogenesis of many diseases, including autoimmune diseases.
Under the terms of the collaboration agreement, Silence will be responsible for preclinical activities and for executing the development programme of each asset until the end of Phase 1, after which Mallinckrodt will assume clinical development and responsibility for the global commercialisation of the assets. Mallinckrodt will fund Phase 1 clinical development including GMP manufacture. Silence will fund all other preclinical activities. Including the
In addition to the two new targets announced today, Mallinckrodt and Silence are already collaborating on the development of a RNAi therapeutic designed to target C3. IND enabling activities have been initiated for the C3 targeted programme (SLN500).
For more information, please contact:
Tel: +44 (0)20 3457 6900
Tel: +44 (0) 20 7597 5970
Tel: +44 (0) 20 3709 5700
Tel: +1 (443) 213-0505
About Mallinckrodt plc
Mallinckrodt is a global business consisting of multiple wholly owned subsidiaries that develop, manufacture, market and distribute specialty pharmaceutical products and therapies. The company's Specialty Brands reportable segment's areas of focus include autoimmune and rare diseases in specialty areas like neurology, rheumatology, nephrology, pulmonology and ophthalmology; immunotherapy and neonatal respiratory critical care therapies; analgesics and gastrointestinal products. Its Specialty Generics reportable segment includes specialty generic drugs and active pharmaceutical ingredients. To learn more about Mallinckrodt, visit www.mallinckrodt.com.
This information is provided by RNS, the news service of the
Quick facts: Silence Therapeutics PLC
Market Cap: £360.29 m
NO INVESTMENT ADVICE
The Company is a publisher. You understand and agree that no content published on the Site constitutes a recommendation that any particular security, portfolio of securities, transaction, or investment strategy is...FOR OUR FULL DISCLAIMER CLICK HERE